论文部分内容阅读
近日在马尼拉举行的一次国际会议透露,目前需采用日常疗法以控制病情的数以百万计的乙型肝炎患者有望实现免除治疗的生活。新的临床数据表明,先前采用抗病毒药物拉米夫定(Iamivudine)进行日常治疗的患者在接受一个疗程(为期48周)的2α-干扰素(商品名为PEGASYS,40KD)治疗后,约1/3的患者可实现持
An international conference recently held in Manila revealed that millions of hepatitis B patients currently requiring routine therapy to control their condition are expected to achieve a life-saving treatment. New clinical data indicate that patients who had previously received routine treatment with the antiviral drug lamivudine had a median duration of about 1 after receiving a course of 48-week treatment of 2α-interferon (PEGASYS 40KD) / 3 patients can be achieved